Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ZNTL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsZentalis doses first patient in pivotal Phase 3 ASPENOVA trial for ovarian cancer drug
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
high
First patient dosed in Phase 3 ASPENOVA trial evaluating azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer, marking start of pivotal study designed to support full FDA approval.
Item 7.01 verify on EDGAR → -
high
Trial will enroll approximately 420 patients comparing azenosertib monotherapy against standard chemotherapy options (paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan).
Item 7.01 verify on EDGAR → -
high
Trial design incorporates FDA feedback for accelerated approval pathway and requirements to convert to full approval, subject to data outcomes.
Item 7.01 verify on EDGAR →
Summary
Zentalis announced a significant clinical milestone: the first patient has been dosed in ASPENOVA, a Phase 3 confirmatory trial for azenosertib in platinum-resistant ovarian cancer. This is the company's lead drug candidate, and the trial is specifically designed to support full FDA approval following the accelerated approval pathway.
The 420-patient randomized study will compare azenosertib monotherapy against standard chemotherapy options. For retail investors, this represents a critical de-risking event. Initiating a Phase 3 trial means the company has cleared regulatory hurdles and secured FDA alignment on trial design. Success in ASPENOVA could lead to full approval and commercial launch in a significant oncology indication.
The trial design was shaped by specific FDA guidance, suggesting regulatory confidence in the approach. Watch for enrollment milestones and interim data readouts. The company will need to demonstrate that azenosertib outperforms standard chemotherapy to achieve full approval. Any updates on enrollment pace or early safety signals will be important indicators of the trial's progress toward potential commercialization.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Zentalis issued a press release under Regulation FD; content not disclosed in the 8-K body itself.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On May 5, 2026, Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) issued the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”) and incorporated herein by reference.
The company issued a press release on May 5, 2026, furnished as Exhibit 99.1. The 8-K body does not disclose the content of the press release itself, only that it was issued under Regulation FD. The actual substance of the disclosure would be in the attached exhibit.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 5, 2026, the Company announced that the first patient has been dosed in the Phase 3 ASPENOVA clinical trial evaluating azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer ("PROC").
Zentalis has initiated patient dosing in ASPENOVA, a pivotal Phase 3 trial for azenosertib in platinum-resistant ovarian cancer. This marks a key regulatory milestone as the trial is designed to support full FDA approval following accelerated approval pathway requirements.
Added in current filing · verify on EDGAR →
ASPENOVA is a Phase 3 randomized, confirmatory clinical trial designed to support full approval of azenosertib in patients with Cyclin E1-positive PROC. The trial is expected to enroll approximately 420 patients and compare azenosertib monotherapy at 400mg QD 5:2 (single daily dose on an intermittent schedule of five days on and two days off) to the investigator's choice of standard-of-care single-agent chemotherapy (paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan).
The trial will enroll approximately 420 patients comparing azenosertib monotherapy against standard chemotherapy options. The design was based on FDA feedback for accelerated approval pathway requirements and potential conversion to full approval.
Added in current filing · verify on EDGAR →
The trial design was based on feedback from the U.S. Food and Drug Administration regarding requirements for seeking approval under the accelerated approval pathway and requirements to support potential conversion to full approval, subject to data outcomes.
The trial design incorporates specific FDA guidance for both accelerated approval and full approval conversion pathways. Success in this trial could lead to full regulatory approval for azenosertib in this indication.
Event · Item 9.01 — Financial Statements and Exhibits
Zentalis filed an 8-K to furnish a press release issued May 5, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The following Exhibit 99.1 relating to Item 7.01 shall be deemed to be furnished, and not filed:
Exhibit No. Description
99.1 Press Release issued on May 5, 2026
The company furnished a press release dated May 5, 2026 under Item 7.01. The 8-K body does not disclose the content of the press release, only that it was issued and attached as an exhibit. Without the exhibit text, no material business event can be identified from this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify